When a sale collapses just before closing, the asset that returns to market is not the asset that left it. It now carries a question no information memorandum will answer: what did the last buyer see? That question sits at the centre of CVC Capital Partners’ reported final talks with EQT over the mainland China contact lens business of Ginko International, parent of the Hydron brand.
Ginko was taken private from the Taiwan stock market in 2022 at an enterprise value of roughly USD 1 billion. In 2025, Advent International reportedly agreed to buy the China unit for more than USD 1.1 billion, tried to reopen the price, and walked away paying a break fee of about USD 10 million. The number now reportedly on the table is USD 700 to 800 million including debt, below the 2022 entry price for the whole company.
The seller is fatigued, rival bidders are gone, and the buyer can write terms rather than price. Whether that seat is opportunity or trap, the price tag does not say.
The Deal
The target is the mainland China contact lens unit of Ginko International: a Cayman holding company above onshore operating entities, an operating headquarters in Danyang, Jiangsu, a sales headquarters in Shanghai, and plants in Danyang and Taiwan. Baring Private Equity Asia (BPEA) led the 2022 take-private, and the asset passed to EQT when the two firms combined that year. Per reports, EQT chose a carve-out (the sale of one unit separated from its parent) over a whole-company sale for speed.
- Seller: EQT, which reportedly wanted at least USD 1 billion.
- Buyer: CVC Capital Partners, in exclusive final talks at a reported USD 700 to 800 million including debt. Terms are undisclosed and the deal may not sign.
- Failed first process: Advent reportedly priced the unit above USD 1.1 billion, about 20x the whole group’s 2024 EBITDA (earnings before interest, taxes, depreciation and amortization), sought a repricing in the summer, was refused, and exited with the break fee.
- Perimeter: mainland only; the Taiwan plant and entity stay outside. In 2022, existing shareholders Hydron International and New Path International joined the buyout consortium with about 28% and 18%.
Structure Breakdown
The seller’s condition comes first. A sponsor that splits an asset to sell faster is working against a clock. Advent’s exit reads as lost nerve or as a diligence finding; the consequence is identical. EQT’s floor and the number on the table sit more than USD 200 million apart, and that gap is the buyer’s lever.
The asset is a combination, not a brand. In China every contact lens, colored ones included, is a Class III medical device: makers need a production licence, sellers a business licence, online sales a separate filing, and advertising law bars endorsements. On top of that barrier, Hydron is one of the few makers able to produce colored lenses in its own silicone hydrogel (SiHy) material, runs international-GMP plants in Danyang and Taiwan with more than RMB 1 billion invested in automation, and sells through optical shops and pharmacies nationwide. Each can be bought; all three under a domestic brand is, on the desk’s read, a category of one. Taiwanese peers chose contract manufacturing and single-digit promotion budgets; Hydron kept its own name on the shelf.
That choice has a price. In its last quarterly figures as a listed company, Ginko showed a gross margin of about 51% and an operating margin around 6%. The 45 points between went to selling cost: if that spend defends a brand, this is a brand company; if it pacifies a channel, it is a distributor, and the two do not share a multiple. Reported 2024 EBITDA growth of about 20% may be operating leverage arriving, or one year of marketing restraint, and is plausibly where Advent tried to reopen the price.
Growth is a mix question, and geography sets the perimeter. Industry research estimates that a wearer moving from reusable hydrogel lenses to SiHy daily disposables can spend up to ten times more per year. Clear lenses belong to four global makers and colored lenses, reportedly about 70% of lens spending on Tmall, are contested by challengers such as Moody and Kilala, so Hydron loses fighting outward and wins by converting inward. Whether the buyer gets a business or a distribution licence depends on what stays in Taiwan.
The Governing Logic
This structure leans almost entirely on Downside Hedge rather than Exit Narrative, because the price carries no margin of safety. The China unit at USD 700 to 800 million implies roughly 12 to 15x the desk’s 2025 EBITDA estimate, near the middle of a discounted cash flow range: a fair price, not a cheap one. At a fair price, alpha needs either conviction in growth or a structure that does not lose, and conviction in an asset the last buyer abandoned at closing is hubris.
Downside Protection
Actual terms are undisclosed. What follows is the architecture the desk would write.
- Split the consideration. Fix cash in the low USD 600 millions and route USD 100 million or more into an earn-out (consideration paid only if agreed targets are met) tied to SiHy disposable revenue share and EBITDA margin. This is Proof-Deferred Pricing: if EQT believes in USD 1 billion, it has no reason to refuse, and a refusal shows where its belief ends. Only on this split does a downside case of flat EBITDA and a 10x exit roughly preserve principal.
- Settle on completion accounts. A locked box fixes price on a historical balance sheet; completion accounts true it up to actual net debt and working capital at closing. Shops, distributors and social resellers sit between shipment and sell-through. Shipments are revenue; only sell-through is cash.
- Reverse the break fee. Last time the buyer paid. This time the seller should pay if foreign-investment review, antitrust or licence transfer fails, with part of the fixed price escrowed for 18 to 24 months until NMPA (National Medical Products Administration) registrations are renewed and transferred.
- Make Taiwan a closing condition. Where the SiHy material, ink and process IP sits, and who employs the core R&D team, defines what is bought. A long-term supply agreement and IP licence with penalties and seller guarantees turns cross-strait risk into a contractual variable. No contract, no deal.
- Match the currency of debt. Onshore RMB borrowing secured on the Danyang plant, net debt capped near 5x EBITDA and dividend restrictions keep debt and assets in one jurisdiction. On desk estimates, deleveraging supplies roughly a quarter of five-year exit value, the one path that works with zero growth.
- Pre-build the exit. A third sponsor-to-sponsor sale has no story left. Build the onshore holding for an A-share or Hong Kong listing from day one, clean up Cayman and Taiwan related-party flows early, and keep the founding side’s minority without a veto.
What Must Be True
1. The 45-point cost gap is brand defense, and normalized EBITDA holds. How rebates, IP-collaboration spend and returns reserves are booked can move EBITDA by tens of millions of dollars and the entry multiple by two to three turns. Falsifier: a normalization adjustment that re-rates the unit as a distributor, or mainland finance that cannot report independently of Taiwan.
2. Reported revenue survives regulatory normalization. Authorities and media describe widespread unqualified lens producers and sellers; social-platform reselling starts for an agent fee of a few hundred yuan, with three or four prices per product. Falsifier: evidence that Hydron leans, even indirectly, on irregular channels, turning enforcement into a headwind against its own sales.
3. Growth comes from disposable conversion, not myopia control. China’s leading orthokeratology lens maker reported 2025 revenue up 2.6%, net profit down 16% and a third straight decline in its core product, as public hospitals cut prices and Hebei-led volume procurement begins. Falsifier: a valuation that counts myopia control as a growth axis.
The compound case is the real threat: Taiwan shipments halted for months, shelves lost to challengers for good, online rules tightening on the one engine that runs online, and a consumer slowdown reversing operating leverage. Together, EBITDA could fall 20 to 30% and the exit multiple slide to 10x. Every path ends the same way: lower normalized EBITDA, a dispute over the earn-out baseline, a delayed close, a repeat of Advent, and a permanent liquidity discount.
The Architect’s Takeaway
If you were building your own deal room, borrow how the USD 800 million is cut, not the number. Counterparties always make claims about traffic, projected earnings or their own contribution. Do not argue; tie part of the consideration to the claim coming true. A counterparty who refuses has completed your diligence.
Settle on sell-through: followers and members are shipments; purchases and renewals are sell-through. Put the break fee on whoever controls the risk. Ask what stays in Taiwan: a community on someone else’s platform, or a reputation built on an employer’s tools, stays behind when you leave, so write the supply contract first, whether a reference letter, an email list or an IP assignment.
Match the currency of debt: a salary funding a side project’s fixed costs is offshore dollars against onshore assets, so cap fixed cost at the project’s own recurring revenue. Decide the exit on day one. And choose the counterparty: crowded deals demand price, which demands capital, while twice-failed processes and tired counterparties accept terms, which demand only logic.
Syndicate’s Note
This is not a deal for a cheap asset. It is a deal for a tired seller, and whatever alpha it holds is written into the earn-out, the settlement mechanics, the direction of the break fee and the Taiwan perimeter before anyone discusses the exit. The headline number is the last word of a long sentence, and a buyer who reads only that word pays for the first buyer’s diligence without ever seeing it. The structure, not the price, is the asset on offer here.
House Verdict: TRACK. The signing terms will test this read directly: price, perimeter and any contingent tranche will show whether the buyer is writing conditions or paying the seller’s number. Falsifier: if CVC signs at or above the USD 1 billion EQT reportedly sought, or a rival bidder re-enters before signing, the tired-seller read is wrong. Under the Verdict Protocol, the label classifies structural learning value, not investment merit.
FAQ
What is an earn-out in private equity?
An earn-out is purchase price paid only if the business hits agreed post-closing targets, such as revenue mix or EBITDA margin. The buyer accepts the headline valuation; the seller carries the projection risk.
Why did Advent walk away from the Ginko International deal?
No party has given an official reason. Advent reportedly tried to renegotiate the price in summer 2025, EQT refused, and Advent exited paying a break fee of about USD 10 million. Whether the trigger was price or a diligence finding remains unconfirmed.
What exactly is CVC buying from EQT?
Only the mainland China contact lens unit of Ginko International, home of the Hydron brand, at a reported USD 700 to 800 million including debt. The Taiwan plant and entity sit outside the perimeter, so supply and IP terms with Taiwan decide whether the buyer owns a business or a distribution licence.
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation. Figures are based on public reports and may be estimates.
For more structural insights and deep-dive video breakdowns, visit Structure Syndicate on YouTube.